Nat Genet:新研究有望为耐药性结核病疫情的出现提供新见解

2013-09-05 MedSci MedSci原创

数个独立研究团队为来自世界不同地区的结核分枝杆菌进行了全基因组测序,成果于9月2日发表在《自然—遗传学》期刊上。相关研究有望为耐药性结核病疫情的出现提供新见解,并为耐药性测试和药物开发提供新标靶。【原文下载】美国马萨诸塞州总医院教授Maha Farhat领衔的研究小组,为全球123种具有代表性的结核分枝杆菌菌株(包括耐药性菌株)进行了全基因组测序和分析。该研究小组借鉴了菌株之间的进化关系,开发出一

数个独立研究团队为来自世界不同地区的结核分枝杆菌进行了全基因组测序,成果于9月2日发表在《自然—遗传学》期刊上。相关研究有望为耐药性结核病疫情的出现提供新见解,并为耐药性测试和药物开发提供新标靶。【原文下载

美国马萨诸塞州总医院教授Maha Farhat领衔的研究小组,为全球123种具有代表性的结核分枝杆菌菌株(包括耐药性菌株)进行了全基因组测序和分析。该研究小组借鉴了菌株之间的进化关系,开发出一种在微生物基因组中搜寻耐药性标记的新方法,并在结核分枝杆菌的基因组中确认了39个与耐药性有关的基因组区段。

来自美国新泽西医学院的David Alland教授与其研究团队,为渗入了一线抗结核药乙胺丁醇的结核分枝杆菌菌株进行了基因组测序,并在63个临床菌株中找到与研究结果相关的发现。他们的功能研究为一个多步骤、包含了基因突变相互作用的乙胺丁醇耐药模型提供了支持理据。

最后,西班牙公共健康研究中心教授Inaki Comas及其同事分析了259个结核分枝杆菌菌株复合体基因组序列,为这种病菌的遗传多样性和与人类宿主一起的进化过程提供了见解。分析结果显示,分枝杆菌菌株复合体约70万年前在非洲出现,然后随人类迁徙而蔓延出非洲。

原文下载

Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PK, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M.Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis.Nat Genet. 2013 Sep 1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048529, encodeId=51772048529f3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 13 21:25:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879659, encodeId=4fb618e965977, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 02 16:25:00 CST 2014, time=2014-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685906, encodeId=2f4016859064d, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 12:25:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733649, encodeId=e4b61e33649e5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Dec 28 20:25:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003950, encodeId=ab03200395005, content=<a href='/topic/show?id=6e4d8038e86' target=_blank style='color:#2F92EE;'>#耐药性结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80387, encryptionId=6e4d8038e86, topicName=耐药性结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 18 08:25:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253883, encodeId=b23612538833e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Sep 07 07:25:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
    2013-10-13 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048529, encodeId=51772048529f3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 13 21:25:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879659, encodeId=4fb618e965977, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 02 16:25:00 CST 2014, time=2014-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685906, encodeId=2f4016859064d, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 12:25:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733649, encodeId=e4b61e33649e5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Dec 28 20:25:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003950, encodeId=ab03200395005, content=<a href='/topic/show?id=6e4d8038e86' target=_blank style='color:#2F92EE;'>#耐药性结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80387, encryptionId=6e4d8038e86, topicName=耐药性结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 18 08:25:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253883, encodeId=b23612538833e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Sep 07 07:25:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
    2014-01-02 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048529, encodeId=51772048529f3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 13 21:25:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879659, encodeId=4fb618e965977, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 02 16:25:00 CST 2014, time=2014-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685906, encodeId=2f4016859064d, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 12:25:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733649, encodeId=e4b61e33649e5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Dec 28 20:25:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003950, encodeId=ab03200395005, content=<a href='/topic/show?id=6e4d8038e86' target=_blank style='color:#2F92EE;'>#耐药性结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80387, encryptionId=6e4d8038e86, topicName=耐药性结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 18 08:25:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253883, encodeId=b23612538833e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Sep 07 07:25:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048529, encodeId=51772048529f3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 13 21:25:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879659, encodeId=4fb618e965977, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 02 16:25:00 CST 2014, time=2014-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685906, encodeId=2f4016859064d, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 12:25:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733649, encodeId=e4b61e33649e5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Dec 28 20:25:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003950, encodeId=ab03200395005, content=<a href='/topic/show?id=6e4d8038e86' target=_blank style='color:#2F92EE;'>#耐药性结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80387, encryptionId=6e4d8038e86, topicName=耐药性结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 18 08:25:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253883, encodeId=b23612538833e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Sep 07 07:25:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
    2013-12-28 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048529, encodeId=51772048529f3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 13 21:25:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879659, encodeId=4fb618e965977, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 02 16:25:00 CST 2014, time=2014-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685906, encodeId=2f4016859064d, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 12:25:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733649, encodeId=e4b61e33649e5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Dec 28 20:25:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003950, encodeId=ab03200395005, content=<a href='/topic/show?id=6e4d8038e86' target=_blank style='color:#2F92EE;'>#耐药性结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80387, encryptionId=6e4d8038e86, topicName=耐药性结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 18 08:25:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253883, encodeId=b23612538833e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Sep 07 07:25:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2048529, encodeId=51772048529f3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 13 21:25:00 CST 2013, time=2013-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879659, encodeId=4fb618e965977, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Jan 02 16:25:00 CST 2014, time=2014-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685906, encodeId=2f4016859064d, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Aug 06 12:25:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733649, encodeId=e4b61e33649e5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Dec 28 20:25:00 CST 2013, time=2013-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003950, encodeId=ab03200395005, content=<a href='/topic/show?id=6e4d8038e86' target=_blank style='color:#2F92EE;'>#耐药性结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80387, encryptionId=6e4d8038e86, topicName=耐药性结核病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Nov 18 08:25:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253883, encodeId=b23612538833e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Sep 07 07:25:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]